Jaka jest cena za AbbVie Inc. (ABBV)

Cena za AbbVie Inc. (ABBV) wynosi $207.15

Jaka jest kapitalizacja rynkowa dla AbbVie Inc. (ABBV)

Kapitalizacja rynkowa dla AbbVie Inc. (ABBV) wynosi $366.28B

AbbVie Inc. (ABBV) Dywidendy

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Rok	Dywidenda (skorygowana o podziały akcji)	Zmień
2026 (TTM)	$1.73	-73.63%
2025	$6.56	5.81%
2024	$6.20	4.73%
2023	$5.92	4.96%
2022	$5.64	8.46%
2021	$5.20	10.17%
2020	$4.72	10.28%
2019	$4.28	19.22%
2018	$3.59	40.23%
2017	$2.56	12.28%
2016	$2.28	12.87%
2015	$2.02	21.69%
2014	$1.66	3.75%
2013	$1.60	0.00%

Rok

Dywidenda (skorygowana o podziały akcji)

Zmień

2026 (TTM)

$1.73

-73.63%

2025

$6.56

5.81%

2024

$6.20

4.73%

2023

$5.92

4.96%

2022

$5.64

8.46%

2021

$5.20

10.17%

2020

$4.72

10.28%

2019

$4.28

19.22%

2018

$3.59

40.23%

2017

$2.56

12.28%

2016

$2.28

12.87%

2015

$2.02

21.69%

2014

$1.66

3.75%

2013

$1.60

0.00%

Rok	Dywidenda	Zmień
2026 (TTM)	$1.73	-73.63%
2025	$6.56	5.81%
2024	$6.20	4.73%
2023	$5.92	4.96%
2022	$5.64	8.46%
2021	$5.20	10.17%
2020	$4.72	10.28%
2019	$4.28	19.22%
2018	$3.59	40.23%
2017	$2.56	12.28%
2016	$2.28	12.87%
2015	$2.02	21.69%
2014	$1.66	3.75%
2013	$1.60	0.00%

Rok

Dywidenda